207 related articles for article (PubMed ID: 30141261)
1. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
[TBL] [Abstract][Full Text] [Related]
3. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
5. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
7. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
[TBL] [Abstract][Full Text] [Related]
8. Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
Lafferty L; Treloar C; Guthrie J; Chambers GM; Butler T
J Viral Hepat; 2017 Feb; 24(2):111-116. PubMed ID: 27778436
[TBL] [Abstract][Full Text] [Related]
9. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
[TBL] [Abstract][Full Text] [Related]
10. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
11. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
[TBL] [Abstract][Full Text] [Related]
12. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
13. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
14. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
Lafferty L; Rance J; Treloar C
Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
16. 'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners.
Khaw FM; Stobbart L; Murtagh MJ
BMC Public Health; 2007 Jun; 7():98. PubMed ID: 17555573
[TBL] [Abstract][Full Text] [Related]
17. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C in Australian prisons: a national needs assessment.
Mina MM; Herawati L; Butler T; Lloyd A
Int J Prison Health; 2016; 12(1):3-16. PubMed ID: 26933988
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project.
Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB
Clin Infect Dis; 2018 Jul; 67(3):460-463. PubMed ID: 29538639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
